From bloodjournal.hematologylibrary.org by guest on June 3, 2013. For personal use only.
Prepublished online March 9, 2004; doi:10.1182/blood-2003-10-3605
Randomized comparison of low dose versus high dose interferon-alfa in chronic myeloid leukemia: Prospective collaboration of three joint trials by the MRC and HOVON groups Hanneke C Kluin-Nelemans, Georgina Buck, Saskia le Cessie, Sue Richards, H B Beverloo, J H Falkenburg, Tim Littlewood, Petra Muus, David Bareford, Hans van der Lelie, Anthony R Green, Klaas J Roozendaal, Alison E Milne, Claire S Chapman and Patricia Shepherd
Articles on similar topics can be found in the following Blood collections Clinical Trials and Observations (3716 articles) Neoplasia (4217 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.
From bloodjournal.hematologylibrary.org by guestMarch on June9,3,2004; 2013. For personal use only. Blood First Edition Paper, prepublished online DOI 10.1182/blood-2003-10-3605
Revised version RANDOMIZED COMPARISON OF LOW DOSE VERSUS HIGH DOSE INTERFERON-ALFA IN CHRONIC MYELOID LEUKEMIA Prospective collaboration of three joint trials by the MRC and HOVON groups
Hanneke C. Kluin-Nelemans1, Georgina Buck2, Saskia le Cessie3, Sue Richards2, H. Berna Beverloo4, J.H. Frederik Falkenburg5, Tim Littlewood6, Petra Muus7, David Bareford8, Hans van der Lelie9, Anthony R Green10, Klaas J. Roozendaal11, Alison E Milne12, Claire S. Chapman13 and Patricia Shepherd14 on behalf of the CML Working Group of the NCRI Adult Leukaemia Working Party and the HOVON trials group. 1
Dept. Hematology, University Medical Center Groningen, The Netherlands; 2Clinical Trial Service Unit, Oxford,
UK; 3Dept. of Medical Statistics, Leiden University Medical Center, The Netherlands; 4Dept Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands; 5
Dept Haematology, Leiden University Medical Center, Leiden, The Netherlands; 6Dept Hematology, The John
Radcliffe Hospital, Oxford, UK; 7Dept Hematology, University Medical Center Nijmegen, The Netherlands; 8City Hospital NHS Trust, Birmingham, UK; 9Dept Hematology, University Medical Center Amsterdam, The Netherlands; 10
Addenbrooke’s NHS Trust, Cambridge, UK; 11Dept Hematology/Oncology, Medical Center OLVG, Amsterdam,
The Netherlands; 12North Hampshire Hospital, Basingstoke, UK; 13Leicester Royal Infirmary, Leicester, UK; 14Dept. of Haematology, Western General Hospital, Edinburgh, Scotland.
Running title: low dose versus high dose IFN-alfa in CML Section: Clinical observations, Interventions, and Therapeutic Trials
Financial support: The UK trials were funded by the Medical Research Council. Research Grants were given by Schering Plough and Glaxo-Wellcome correspondence
Dr Pat Shepherd; Department of Haematology Western General Hospital; Edinburgh EH4 2XU email:
[email protected]; tel: 0131 537 1633; fax: 0131 537 2552
Word count :
4291
1 Copyright (c) 2004 American Society of Hematology
From bloodjournal.hematologylibrary.org by guest on June 3, 2013. For personal use only.
ABSTRACT The optimal dose of interferon-alfa (IFN) for CML is unknown. Retrospective analyses suggest that low doses are as effective as high doses, with less toxicity and fewer patients abandoning the drug. The Dutch HOVON and British Medical Research Council cooperative groups jointly performed randomized trials in newly diagnosed CML comparing high dose IFN (5 MIU/m2 daily) with low dose (3 MIU, 5 times a week). Both arms allowed additional hydroxyurea to keep the white blood cells
